FORMA Therapeutics has expanded its tumor metabolism research alliance with J&J subsidiary Janssen Biotech to an executed license agreement. As part of Janssen’s election to execute a license agreement, FORMA will receive additional undisclosed payments, as well as potential future milestones and royalties on each product. Janssen has also expanded the initial collaboration to include new targets.
 
“This expanded alliance with Janssen demonstrates FORMA’s ability to execute and deliver quality drug programs to our partners. As we now take a defined program through the next stages of development for Janssen, we will be leveraging additional innovative translational insights through our strategic partnership,” said Steven Tregay, Ph.D., president and chief executive officer, FORMA Therapeutics.
 
“In order to better understand the interplay of targets within each of four areas (tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions), FORMA initially selects 10 to 20 key targets in each area to examine and quickly creates novel drugs to drive a true chemical biology approach. We look forward to continuing our partnership with Janssen and leveraging capabilities from both groups to advance these programs,” said Kenneth W. Bair, Ph.D., chief scientific officer and head of R&D, FORMA Therapeutics.